At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 2, 2026 at 06:50 ET
Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biotech. The focus remains on upcoming catalysts: NDA submission for deucrictibant IR in 1H2026 and topline data from the CHAPTER-3 pivotal trial in 3Q2026. Cash runway of €292M supports operations through key inflection points.
- EPS of $-0.60 vs. consensus of $-0.62 (3% beat), revenue $0 in line with expectations
- Cash and cash equivalents: €292 million as of December 31, 2025
- NDA submission for deucrictibant IR (on-demand HAE treatment) on track for 1H2026
- Topline data from CHAPTER-3 trial (prophylactic HAE treatment) expected in 3Q2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access